Home
Random
Nearby
Log in
Settings
Donate
About Wikidata
Disclaimers
Search
(Q37021822)
Watch
English
Therapeutic strategies in the management of patients with chronic hepatitis B virus infection.
scientific article
In more languages
edit
Statements
instance of
scholarly article
1 reference
stated in
Europe PubMed Central
PubMed publication ID
18053766
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18053766%20AND%20SRC:MED&resulttype=core&format=json
retrieved
28 December 2019
review article
1 reference
stated in
Europe PubMed Central
title
Therapeutic strategies in the management of patients with chronic hepatitis B virus infection
(English)
1 reference
stated in
Europe PubMed Central
PubMed publication ID
18053766
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18053766%20AND%20SRC:MED&resulttype=core&format=json
retrieved
28 December 2019
main subject
patient
0 references
Hepatitis B virus
1 reference
based on heuristic
inferred from title
chronic hepatitis B
1 reference
based on heuristic
inferred from title
chronic hepatitis
1 reference
based on heuristic
inferred from title
author
George Papatheodoridis
series ordinal
1
1 reference
stated in
Europe PubMed Central
PubMed publication ID
18053766
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18053766%20AND%20SRC:MED&resulttype=core&format=json
retrieved
28 December 2019
author name string
Spilios Manolakopoulos
series ordinal
2
1 reference
stated in
Europe PubMed Central
PubMed publication ID
18053766
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18053766%20AND%20SRC:MED&resulttype=core&format=json
retrieved
28 December 2019
Geoffrey Dusheiko
series ordinal
3
1 reference
stated in
Europe PubMed Central
PubMed publication ID
18053766
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18053766%20AND%20SRC:MED&resulttype=core&format=json
retrieved
28 December 2019
Athanasios J Archimandritis
series ordinal
4
1 reference
stated in
Europe PubMed Central
PubMed publication ID
18053766
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18053766%20AND%20SRC:MED&resulttype=core&format=json
retrieved
28 December 2019
publication date
28 November 2007
1 reference
stated in
Europe PubMed Central
PubMed publication ID
18053766
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18053766%20AND%20SRC:MED&resulttype=core&format=json
retrieved
28 December 2019
published in
Lancet Infectious Diseases
1 reference
stated in
Europe PubMed Central
PubMed publication ID
18053766
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18053766%20AND%20SRC:MED&resulttype=core&format=json
retrieved
28 December 2019
volume
8
1 reference
stated in
Europe PubMed Central
PubMed publication ID
18053766
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18053766%20AND%20SRC:MED&resulttype=core&format=json
retrieved
28 December 2019
issue
3
1 reference
stated in
Europe PubMed Central
PubMed publication ID
18053766
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18053766%20AND%20SRC:MED&resulttype=core&format=json
retrieved
28 December 2019
page(s)
167-178
1 reference
stated in
Europe PubMed Central
PubMed publication ID
18053766
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18053766%20AND%20SRC:MED&resulttype=core&format=json
retrieved
28 December 2019
cites work
Hepatitis B virus infection
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970264-5
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Hepatitis B: an important public health issue
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970264-5
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Global programme for control of hepatitis B infection
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970264-5
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Management of hepatitis B: 2000--summary of a workshop
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970264-5
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Review article: current management of chronic hepatitis B.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970264-5
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Emerging treatments in chronic hepatitis B.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970264-5
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Chronic hepatitis B.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970264-5
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Natural history and prognosis of hepatitis B.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970264-5
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
The natural history of chronic hepatitis B virus infection
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970264-5
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Hepatitis B e antigen-negative chronic hepatitis B: natural history and treatment
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970264-5
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Seroconversion from Hepatitis B e Antigen to Antibody in Chronic Type B Hepatitis
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970264-5
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Clinical, virologic and histologic outcome following seroconversion from HBeAg to anti-HBe in chronic hepatitis type B
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970264-5
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Spontaneous hepatitis B e antigen to antibody seroconversion and reversion in Chinese patients with chronic hepatitis B virus infection
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970264-5
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Hepatitis B virus genotype B is associated with earlier HBeAg seroconversion compared with hepatitis B virus genotype C.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970264-5
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Significance of hepatitis B genotype in acute exacerbation, HBeAg seroconversion, cirrhosis-related complications, and hepatocellular carcinoma
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970264-5
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Hepatitis B virus genotypes in the United States: results of a nationwide study
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970264-5
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Diagnosis and management of pre-core mutant chronic hepatitis B.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970264-5
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Hepatitis B e antigen-negative chronic hepatitis B.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970264-5
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Wild-type and e antigen-minus hepatitis B viruses and course of chronic hepatitis.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970264-5
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
The role of pre-core hepatitis B virus mutants on the long-term outcome of chronic hepatitis B virus hepatitis. A longitudinal study
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970264-5
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
The development of cirrhosis in patients with chronic type B hepatitis: A prospective study
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970264-5
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Natural history and prognostic factors for chronic hepatitis type B
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970264-5
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Survival in chronic hepatitis B. An analysis of 379 patients
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970264-5
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Survival and prognostic factors in 366 patients with compensated cirrhosis type B: a multicenter study. The Investigators of the European Concerted Action on Viral Hepatitis (EUROHEP)
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970264-5
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Survival and prognostic indicators in hepatitis B surface antigen-positive cirrhosis of the liver
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970264-5
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Hepatitis B virus. The major etiology of hepatocellular carcinoma
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970264-5
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970264-5
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2005 update
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970264-5
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
The natural history of asymptomatic hepatitis B surface antigen carriers
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970264-5
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: an update
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970264-5
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Predicting cirrhosis risk based on the level of circulating hepatitis B viral load
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970264-5
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970264-5
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Intrahepatic hepatitis B virus covalently closed circular DNA can be a predictor of sustained response to therapy
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970264-5
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Antiviral therapy of chronic hepatitis B: can we clear the virus and prevent drug resistance?
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970264-5
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Long-term follow-up of HBeAg-positive patients treated with interferon alfa for chronic hepatitis B
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970264-5
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Long-term remission of chronic hepatitis B after alpha-interferon therapy
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970264-5
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Long-term outcome of hepatitis B e antigen-positive patients with compensated cirrhosis treated with interferon alfa. European Concerted Action on Viral Hepatitis (EUROHEP)
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970264-5
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Long-term follow-up of alpha-interferon treatment of patients with chronic hepatitis B.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970264-5
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
The long-term outcome of interferon-alpha treated and untreated patients with HBeAg-negative chronic hepatitis B
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970264-5
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Outcome of hepatitis B e antigen-negative chronic hepatitis B on long-term nucleos(t)ide analog therapy starting with lamivudine
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970264-5
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Long-term beneficial effect of interferon therapy in patients with chronic hepatitis B virus infection
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970264-5
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Interferon therapy in HBeAg positive chronic hepatitis reduces progression to cirrhosis and hepatocellular carcinoma
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970264-5
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Long-term follow-up of interferon alfa treatment in Chinese patients with chronic hepatitis B infection: The effect on hepatitis B e antigen seroconversion and the development of cirrhosis-related complications
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970264-5
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
The relationship between HBV-DNA levels and cirrhosis-related complications in Chinese with chronic hepatitis B.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970264-5
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Chronic hepatitis B: update of recommendations
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970264-5
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
The treatment of chronic viral hepatitis
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970264-5
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Nucleoside analogues for chronic hepatitis B: antiviral efficacy and viral resistance
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970264-5
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Effect of Alpha-Interferon Treatment in Patients with Hepatitis B e Antigen-Positive Chronic Hepatitis B
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970264-5
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970264-5
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970264-5
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Lamivudine as initial treatment for chronic hepatitis B in the United States
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970264-5
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970264-5
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970264-5
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Interferon alpha treatment and retreatment of hepatitis B e antigen-negative chronic hepatitis B.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970264-5
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Long-term suppression of hepatitis B e antigen-negative chronic hepatitis B by 24-month interferon therapy.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970264-5
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970264-5
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Efficacy of lamivudine in patients with hepatitis B e antigen-negative/hepatitis B virus DNA-positive (precore mutant) chronic hepatitis B. Lamivudine Precore Mutant Study Group
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970264-5
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Long-term follow-up of patients with anti-HBe/HBV DNA-positive chronic hepatitis B treated for 12 months with lamivudine
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970264-5
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970264-5
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970264-5
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970264-5
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Asia Hepatitis Lamivudine Study Group
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970264-5
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Long-term safety of lamivudine treatment in patients with chronic hepatitis B.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970264-5
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: results after 3 years of therapy
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970264-5
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Four years of lamivudine treatment in Chinese patients with chronic hepatitis B.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970264-5
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Course of virologic breakthroughs under long-term lamivudine in HBeAg-negative precore mutant HBV liver disease
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970264-5
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Four years of treatment with lamivudine: clinical and virological evaluations in HBe antigen-negative chronic hepatitis B.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970264-5
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Clinical outcome of HBeAg-negative chronic hepatitis B in relation to virological response to lamivudine
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970264-5
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970264-5
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970264-5
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
A randomized, controlled trial of combination therapy for chronic hepatitis B: comparing pegylated interferon-alpha2b and lamivudine with lamivudine alone
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970264-5
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
A 1-year trial of telbivudine, lamivudine, and the combination in patients with hepatitis B e antigen-positive chronic hepatitis B
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970264-5
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Durability of HBeAg seroconversion following antiviral therapy for chronic hepatitis B: relation to type of therapy and pretreatment serum hepatitis B virus DNA and alanine aminotransferase
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970264-5
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Durability of serologic response after lamivudine treatment of chronic hepatitis B.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970264-5
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Hepatitis B e antigen seroconversion after lamivudine therapy is not durable in patients with chronic hepatitis B in Korea
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970264-5
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Effect of virological response on post-treatment durability of lamivudine-induced HBeAg seroconversion
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970264-5
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Efficacy of long-term lamivudine monotherapy in patients with hepatitis B e antigen-negative chronic hepatitis B.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970264-5
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Sustained response after a 2-year course of lamivudine treatment of hepatitis B e antigen-negative chronic hepatitis B.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970264-5
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Prompt relapse of viremia after lamivudine discontinuation in e-minus chronic hepatitis B patients completely responders during 5 years of therapy
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970264-5
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Lamivudine for patients with chronic hepatitis B and advanced liver disease
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970264-5
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
HBV drug resistance: mechanisms, detection and interpretation
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970264-5
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Viral dynamics in hepatitis B virus infection
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970264-5
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Mutation rate of the hepadnavirus genome
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970264-5
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Detection of YMDD motif mutations in some lamivudine-untreated asymptomatic hepatitis B virus carriers
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970264-5
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Emergence of YMDD motif mutant of hepatitis B virus during short-term lamivudine therapy in South Korea
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970264-5
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Emergence and selection of HBV variants in an anti-HBe positive patient persistently infected with quasi-species
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970264-5
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Clinical relevance of hepatitis B viral mutations
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970264-5
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Histological outcome during long-term lamivudine therapy.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970264-5
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Clinical course of lamivudine monotherapy in patients with decompensated cirrhosis due to HBeAg negative chronic HBV infection
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970264-5
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Lamivudine treatment for decompensated cirrhosis resulting from chronic hepatitis B
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970264-5
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Adefovir-resistant hepatitis B can be associated with viral rebound and hepatic decompensation
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970264-5
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Identification and characterization of mutations in hepatitis B virus resistant to lamivudine. Lamivudine Clinical Investigation Group
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970264-5
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Hepatitis B virus mutations associated with antiviral therapy
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970264-5
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Factors associated with hepatitis B virus DNA breakthrough in patients receiving prolonged lamivudine therapy.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970264-5
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Lamivudine monotherapy in HBeAg-negative chronic hepatitis B: prediction of response-breakthrough and long-term clinical outcome.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970264-5
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Resistance to adefovir dipivoxil therapy associated with the selection of a novel mutation in the HBV polymerase
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970264-5
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Entecavir resistance is rare in nucleoside naïve patients with hepatitis B
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970264-5
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Clinical emergence of entecavir-resistant hepatitis B virus requires additional substitutions in virus already resistant to Lamivudine
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970264-5
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Retreatment of chronic hepatitis B e antigen-positive patients with recombinant interferon alfa-2a. The European Concerted Action on Viral Hepatitis (EUROHEP)
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970264-5
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Acute exacerbation of chronic hepatitis B virus infection after withdrawal of lamivudine therapy
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970264-5
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Virologic response and resistance to adefovir in patients with chronic hepatitis B.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970264-5
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Tenofovir disoproxil fumarate
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970264-5
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Tenofovir for patients with lamivudine-resistant hepatitis B virus (HBV) infection and high HBV DNA level during adefovir therapy
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970264-5
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Resistance to lamivudine therapy: is there more than meets the eye?
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970264-5
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Cellular and virological mechanisms of HBV drug resistance
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970264-5
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970264-5
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
A dose-ranging study of the efficacy and tolerability of entecavir in Lamivudine-refractory chronic hepatitis B patients
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970264-5
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Long-term therapy of chronic hepatitis B with lamivudine.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970264-5
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Adefovir dipivoxil in the treatment of chronic hepatitis B virus infection
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970264-5
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Entecavir for Treatment of Lamivudine-Refractory, HBeAg-Positive Chronic Hepatitis B
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970264-5
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Mutations in hepatitis B DNA polymerase associated with resistance to lamivudine do not confer resistance to adefovir in vitro
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970264-5
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Adefovir dipivoxil added to ongoing lamivudine therapy in patients with lamivudine-resistant hepatitis B e antigen-negative chronic hepatitis B.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970264-5
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Adefovir rapidly suppresses hepatitis B in HBeAg-negative patients developing genotypic resistance to lamivudine.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970264-5
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Switching to adefovir monotherapy after emergence of lamivudine-resistant mutations in patients with liver cirrhosis
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970264-5
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Adding-on versus switching-to adefovir therapy in lamivudine-resistant HBeAg-negative chronic hepatitis B.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970264-5
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Rescue therapy for drug resistant hepatitis B: another argument for combination chemotherapy?
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970264-5
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Selection of a hepatitis B virus strain resistant to adefovir in a liver transplantation patient.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970264-5
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Susceptibility to antivirals of a human HBV strain with mutations conferring resistance to both lamivudine and adefovir.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970264-5
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Variant of hepatitis B virus with primary resistance to adefovir
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970264-5
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Antiviral drug resistance: clinical consequences and molecular aspects
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970264-5
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Drugs in development for hepatitis B.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970264-5
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Treatment alternatives for chronic hepatitis B virus infection: a cost-effectiveness analysis
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970264-5
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Cost-effectiveness analysis of lamivudine and adefovir dipivoxil in the treatment of patients with HBeAg-negative chronic hepatitis B.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970264-5
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Identifiers
DOI
10.1016/S1473-3099(07)70264-5
1 reference
stated in
Europe PubMed Central
PubMed publication ID
18053766
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18053766%20AND%20SRC:MED&resulttype=core&format=json
retrieved
28 December 2019
PubMed publication ID
18053766
1 reference
stated in
Europe PubMed Central
PubMed publication ID
18053766
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18053766%20AND%20SRC:MED&resulttype=core&format=json
retrieved
28 December 2019
Sitelinks
Wikipedia
(0 entries)
edit
Wikibooks
(0 entries)
edit
Wikinews
(0 entries)
edit
Wikiquote
(0 entries)
edit
Wikisource
(0 entries)
edit
Wikiversity
(0 entries)
edit
Wikivoyage
(0 entries)
edit
Wiktionary
(0 entries)
edit
Multilingual sites
(0 entries)
edit